Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAK 186

Next Previous
Search
Drug Profile

TAK 186

Alternative Names: EGFR x CD3 COBRA; MVC-101; TAK-186

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Maverick Therapeutics
  • Developer Takeda
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 18 May 2021 Presage Biosciences and Maverick Therapeutics plans a phase I trial for Solid tumours (Combination therapy, In adults, In the elderly) in Australia(Intratumoural, Injection), in July 2021 (NCT04891718)
  • 13 Apr 2021 Takeda anticipates the approval of TAK 186 for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in 2027 (Takeda pipeline, April 2021)
  • 08 Mar 2021 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Australia (Parenteral) (NCT04844073) (Maverick therapeutics pipeline, March 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top